

## SUPPLEMENTARY INFORMATION FOR

### **Downregulation of circRNA DMNT3B contributes to diabetic retinal vascular dysfunction through targeting miR-20b-5p and BAMBI**

Ke Zhu<sup>a</sup>, Xin Hu<sup>b</sup>, Han Chen<sup>a</sup>, Fang Li<sup>b</sup>, Ning Yin<sup>b</sup>, Ai-Lin Liu<sup>b</sup>, Kun Shan<sup>a</sup>, Yao-Wu Qin<sup>a</sup>, Xin Huang<sup>a</sup>, Qing Chang<sup>a</sup>, Ge-Zhi Xu<sup>a,\*</sup>, Zhongfeng Wang<sup>b,\*\*</sup>

<sup>a</sup> Department of Ophthalmology and Vision Science, Eye and Ear Nose Throat Hospital, Shanghai Key Laboratory of Visual Impairment and Restoration, NHC Key Laboratory of Myopia, Key Laboratory of Myopia, Chinese Academy of Medical Sciences, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Fudan University, Shanghai 200031, China


<sup>b</sup> Department of Neurology, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Zhongshan Hospital, Fudan University, Shanghai 200032, China.

**Supplementary Table S1. miRNA inhibitor, miRNA mimic siRNA target and FISH probe sequences used in this study.**


<b>miRNA inhibitor sequences</b>		
hsa-miR-20b-5p inhibitor		CUACCUGCACUAUGAGCACUUUG
miR inhibitor negative control		CAGUACUUUUGUGUAGUACAAA
<b>miRNA mimic sequences</b>		
hsa-miR-20b-5p mimic	Forward	CAAAGUGCUCUAUAGUGCAGGUAG
	Reverse	CUACCUGCACUAUGAGCACUUUG
miR mimic negative control	Forward	UUUGUACUACACAAAAGUACUG
	Reverse	CAGUACUUUUGUGUAGUACAAA
<b>siRNA target sequences</b>		
siBAMBI		GAAGACATGTGCAATTACA
siRNA NC		TTCTCCGAACGTGTCACGT
<b>Probes for FISH</b>		
hsa-miR-20b-5p-Cy3		CTACCTGCACTATGAGCACTTG
hsa-circDNMT3B-FITC		TCTGCAGAGACCTGGTTGCGT

**Supplementary Table S2. Primers used in this study.**


Primer sequences		
rno-miR-20b-5p	Forward	CAAAGTGCTCATAGTGCAGGTA
hsa-miR-20b-5p	Forward	CAAAGTGCTCATAGTGCAGGTA
hsa-BAMBI	Forward	GGCAGCATCACAGTAGCATC
	Reverse	GATCGCCACTCCAGCTACAT
rno-BAMBI	Forward	CTCCTCCCAAGAGTGAAGCC
	Reverse	AAGATCAGTCCGCCAGCAAT
	Reverse	GGGACCTTGGTTAGGTGCAG
hsa-TCF7L2	Forward	CCGACGTAGACCCCAAACA
	Reverse	ATTTGTCCTACGGTGCCAGG
hsa-PTEN	Forward	CGGTGTCATAATGTCITTCAGC
	Reverse	TGAAGGCGTATACAGGAACAAT
hsa-lkb1	Forward	CACCGAGGTCATCTACCAGC
	Reverse	ACCTTGCCGTAAGAGCCTTC
hsa-CDKN1A	Forward	CTCAAATCGTCCAGCGACCT
	Reverse	GACTCCTTGTTCGGCTGCTA
hsa-BMPR2	Forward	CCAAGGTCTTGCTGATACGG
	Reverse	CTACCATGGACCATCCTGCT
hsa-ZBTB4	Forward	ACCTTCCTCAGCTTCCATGC
	Reverse	TGCTCAGCCACAGAACAGAG
hsa-circDNMT3B	Forward	GAGACTCATTGGAGACCAGC
	Reverse	CAGAGACCTGGTTGCGTGTT
hsa-DNMT3B mRNA	Forward	CAGCCCTGGAGACTCATTGG
	Reverse	GGTTGCGTGTGTTGGGTTT
hsa-circTNFRSF21	Forward	GGTGTTTGTTAGCATGAACTCAAC
	Reverse	CCTGAAGGTTTGGGAGGGTC
hsa- $\beta$ -actin	Forward	GATGAGATTGGCATGGCTTT
	Reverse	GTCACCTTCACCGTTCCAGT
rno- $\beta$ -actin	Forward	CTGTCCCTGTATGCCTCTG
	Reverse	ATGTCACGCACGATTTCC
hsa-circDNMT3B vector (pLCDH-ciR)	Forward	CGGAATTCTGAAATATGCTATCTTACAGGTCTCTGCAGACAAACTGGTG
	Reverse	CGGGATCCTCAAGAAAAATATATTCACCTGGTTGCGTGTGTTGGGTT
hsa-circDNMT3B vector (pAAV2/DJ-CMV-GFP)	Forward	CGGAATTCTGAAATATGCTATCTTACAGGTCTCTGCAGACAAACTGGTG
	Reverse	CGGGATCCTCAAGAAAAATATATTCACCTGGTTGCGTGTGTTGGGTT




**Supplementary Fig. S1. The Maps of luciferase reporter vectors used in this study. (a) Map of pmiR-RB-REPORT vector. (b) Map of psiCHECK2 vector.**




**Supplementary Fig. S2. Changes of tight junction-related protein levels in HRMECs under normal glucose conditions.** (a) Representative Western blotting results show the changes in protein levels of ZO-1, occludin, and claudin-5 in HRMECs which were transfected with miR-20b-5p inhibitor or miR inhibitor NC in 5 mM glucose (normal glucose, NG) medium. (b-d) Bar chart summarizing the relative density of immunoblot bands of ZO-1 (n = 4) (b), occludin (n = 4) (c), and claudin-5 (n = 3) (d). All data are normalized to control. \*  $p < 0.05$  and \*\*  $p < 0.01$  vs. control; #  $p < 0.05$  vs. miR-20b-5p inhibitor group. All *in vitro* experiments: n = 3 or 4 biological replicates  $\times$  3 technical replicates. Data presented as means with error bars representing standard deviation (SD). Abbreviations: HRMEC = human retinal microvascular endothelial cells, NC = negative control, ZO-1 = zonula occludens-1.



**Supplemental Fig. S3. Expression levels of some candidate mRNAs.** (a-g) Bar charts showing the changes of TGFβR2 (a), TCF7L2 (b), PTEN (c), Ikb1 (d), CDKN1A (e), BMPR2 (f) and ZBTB4 (g) levels, assayed by qRT-PCR, in HRMECs cultured in 5 mM glucose (normal glucose, NG), 5 mM glucose plus 25 mM mannitol (Mannitol), or 30 mM glucose (HG) medium for 24 h, 48 h, and 72 h, respectively. Data are normalized to corresponding NG groups. n = 3 for each group, \*  $p < 0.05$  and \*\*  $p < 0.01$  vs. NG. (h-k) Bar charts showing the changes of PTEN (h), Ikb1 (i), CDKN1A (j) and BMPR2 (k) levels in HRMECs under different conditions. HRMECs were transfected with miR NC (control) or miR-20b-5p inhibitor (miR-20b-5p inhibitor group) with or without HG treatment. Data are normalized to control. n = 4 for each group, \*  $p < 0.05$  vs. control, #  $p < 0.05$ , ##  $p < 0.01$  vs. HG group. All *in vitro* experiments: n = 3 or 4 biological replicates  $\times$  3 technical replicates. All data presented as means with error bars representing standard deviation (SD). Abbreviations: BMPR2 = bone morphogenetic protein receptor type 2, CDKN1A = cyclin-dependent kinase inhibitor 1A, HG = high glucose, HRMEC = human retinal microvascular endothelial cells, miR = microRNA, NC = negative control, NG = normal glucose, PTEN = phosphatase and tensin homolog, qRT-PCR = quantitative reverse-transcription polymerase chain reaction. TCF7L2 = transcription factor 7 like 2, TGFβR2 = transforming growth factor beta receptor 2, ZBTB4 = zinc finger and BTB domain containing 4.



**Supplementary Fig. S4. Expression levels of circTNFRSF21.** (a) The Sanger sequencing showing that the amplified product of divergent primers was consistent with circTNFRSF21 sequence in circBase. (b) qRT-PCR results reveal the changes of circTNFRSF21 levels in HRMECs cultured in 5 mM glucose (**normal glucose, NG**), 5 mM glucose plus 25 mM mannitol (Mannitol), or 30 mM glucose (HG) medium for 24 h, 48 h, and 72 h, respectively. Data are normalized to corresponding NG groups.  $n = 3$  for each group. All *in vitro* experiments:  $n = 3$  biological replicates  $\times$  3 technical replicates. Data presented as means with error bars representing standard deviation (SD). Abbreviations: HG = high glucose, HRMEC = human retinal microvascular endothelial cells, **NG = normal glucose**, qRT-PCR = quantitative reverse-transcription polymerase chain reaction, TNFRSF21 = TNF receptor superfamily member 21.



**Supplementary Fig. S5. Expression levels of circDNMT3B.** Summarized data showing the changes of circDNMT3B levels in HRMECs, assayed with qRT-PCR, under different conditions. All data are normalized to ciR NC group. n = 6 for each group, \*  $p < 0.05$  vs. ciR NC group, and ###  $p < 0.001$  vs. HG. All *in vitro* experiments: n = 3 or 4 biological replicates  $\times$  3 technical replicates. Data presented as means with error bars representing standard deviation (SD). Abbreviations: ciR = circular RNA, DNMT3B = DNA methyltransferase 3 beta, HG = high glucose, HRMEC = human retinal microvascular endothelial cells, miR = micro RNA, NC = negative control, qRT-PCR = quantitative reverse-transcription polymerase chain reaction.